NCT04560127 2025-07-10
Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT06831175 2025-06-03
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
West China Hospital
Phase 2 Recruiting
NCT06764368 2025-01-08
Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors
Beijing Chest Hospital
Phase 2 Not yet recruiting
NCT04318730 2024-07-17
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
West China Hospital
Phase 2 Recruiting
NCT03048877 2023-04-12
Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase 3 Unknown